SCHEMBL1654665

SCHEMBL1654665

COc1ccc(-c2c(-c3c(C)csc3C)n(C#N)c3ccc(Cl)cc23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 1/20 0.37
MAOA P21397 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA12 O43570 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
CSF1R P07333 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12777876 0.71 CYP2A6 (0.36) CSF1RALDH1A1MAPTMEN1KMT2A
SCHEMBL1653139 0.71 MAP2 (0.53) MAP2CSF1R
SCHEMBL1654834 0.67 CYP2A6 (0.33) MAP2CSF1RMEN1KMT2ACYP2A6
SCHEMBL1654838 0.67 CYP2A6 (0.32) CSF1RCYP2A6
SCHEMBL13098625 0.64 ALDH1A1 (0.50) ALDH1A1HPGDMAPTNPSR1RXFP1
SCHEMBL1653145 0.63 BRD4 (0.48) ALDH1A1L3MBTL1
SCHEMBL1636841 0.63 TP53 (0.48) ALDH1A1HPGDMAPTNPSR1KMT2A
SCHEMBL30345966 0.60 AURKA (0.52) MAP2CA1CA2CA12CA3
SCHEMBL432457 0.60 AURKA (0.52) MAP2CA1CA2CA12CA3
SCHEMBL1652825 0.59 KDM4E (0.40) MAOACA1CA2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486010-B1 ESTROGEN RECEPTOR LIGANDS KARO PHARMA AB (SE) 2019-06-12 EP disclosed
EP-2486010-B1 ESTROGEN RECEPTOR LIGANDS KARO PHARMA AB (SE) 2019-06-12 EP disclosed
US-8710243-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-04-29 US disclosed
EP-2486010-A2 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2012-08-15 EP disclosed
US-20120202861-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2012-08-09 US disclosed
US-20120202861-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2012-08-09 US disclosed
US-20120202861-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2012-08-09 US disclosed
WO-2011042473-A2 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202861-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 MAP2 4425/4885MAOA 3961/4885CA1 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.